As usual PaulSnowman makes a lot of sense!...
"You can look back at previous Quad Witching dates, and see the volume wasn’t anywhere near yesterday’s 57M. Yes there was a big money option’s battle over $2.61, but some HF’s got caught with their pants down with the Sclilex SP102 final results PR. The Sorrento PR wasn’t a flub like Abivertinib, and the follow up PR on the Sclilex website was even better. Ji/ BOD seemed to have learned not to overstate, maybe thats the Sclilex management rubbing off on them, and instead are understating.
Apply for SP102 NDA in 2023? Definitely understating. We should see approval in the 4th quarter 2022 / 1st quarter 2023. Vickers merger in 3rd quarter? The full readout is out, and the only thing out of their control are when the multiple peer review are done. When the reviews are released and as expected are strongly positive you can also expect a Vickers PR release on a shareholders merger voting date soon after. Lastly, with sales reps in all 50 states and SP102 being fast tracked, well tolerated, non opioid (image the press when released on a non opioid drug when approved), and the only drug thats not black labeled (which by the way both doctors / hospital lawyers and insurers will be extremely happy when it comes to litigation) you can expect a fast roll out. This is a 99.9% no brainer. No wonder Ji made that Sclilex share grab. I’m buying both Sorrento shares at these levels, and post Sclilex shares. BP’s will want to be invited to the dance when it comes time to licensing deals outside the US."
"The refusal of the real is the number one dogma of our time" Rene Girard
